Summary of Krystal Biotech Q1 2026 Earnings Call

1Key Financial Results and Metrics

Net Revenue: $116.4 million for Q1 2026, a 9% sequential increase from Q4 2025 and a 32% increase year-over-year.

Cumulative Revenue: Over $846 million since the launch of VYJUVEK.

Gross Margin: 95%, slightly up from 94% in Q1 2025.

Net Income: $55.9 million, translating to $1.91 per basic share and $1.83 per diluted share, up from $35.7 million and $1.24 per basic share in Q1 2025.

Operating Expenses: R&D expenses were $15.3 million, and G&A expenses increased to $41 million, primarily due to headcount and legal costs.

Cash Position: Exceeded $1 billion, providing strong support for pipeline and commercial efforts.

2Strategic Updates and Business Highlights

VYJUVEK Launch: Continued global revenue growth, with significant early traction in Europe and Japan, contributing $28.9 million in net revenue.

Regulatory Designations: FDA granted platform technology designations for KB407 (CF) and KB111 (Hailey-Hailey), enhancing regulatory interactions and development plans.

Pipeline Development: Two registrational study readouts expected in 2026 and two more in 2027, with ongoing studies for KB803 (corneal abrasions) and KB801 (neurotropic keratitis).

International Expansion: Plans to launch in Italy and Spain later in 2026, with ongoing pricing negotiations in Germany and France.

3Forward Guidance and Outlook

U.S. Growth: Anticipated continued growth in the U.S. market, although the start-stop treatment paradigm may lead to variability in quarterly performance.

International Market Penetration: Focus on deepening penetration in existing markets and expanding into new ones, with positive expectations for reimbursement outcomes.

Clinical Milestones: Six potential data readouts expected by year-end, including two registrational studies.

4Bad News, Challenges, or Points of Concern

Insurance Dynamics: Increased scrutiny from insurance companies regarding treatment cycles may complicate patient access and reimbursement.

Market Variability: Fluctuations in quarterly performance due to the start-stop nature of treatments and ongoing pricing negotiations in Europe may create uncertainty.

Regulatory Risks: The need for additional data and validation for new treatments could delay timelines for registrational studies.

5Notable Q&A Insights

U.S. Growth Trajectory: Management expressed confidence in long-term growth despite short-term fluctuations, emphasizing strong demand metrics and increasing prescriber base.

Pipeline Development: The company is actively engaging with the FDA regarding innovative trial designs for CF treatments, aiming for a registrational trial in early 2027.

International Pricing: Negotiations in Spain are expected to align with other European markets, but outcomes remain uncertain.

Patient Administration: The introduction of home administration options for VYJUVEK has positively impacted patient engagement and treatment adherence. Overall, Krystal Biotech is positioned for significant growth with a strong financial foundation, ongoing international expansion, and a robust clinical pipeline, despite facing challenges related to insurance dynamics and market variability.